TABLE 4.
Outcomes | Vaccine group (n = 105) | Control group (n = 155) | p Value |
---|---|---|---|
No. of oocytes retrieved | 14.74 ± 5.99 | 13.30 ± 5.82 | 0.053 |
No. of MII oocytes | 11.67 ± 4.87 | 10.54 ± 5.05 | 0.073 |
No. of 2PN cleavage‐stage embryos | 8.59 ± 4.47 | 7.75 ± 4.14 | 0.120 |
No. of blastocysts | 5.06 ± 3.17 | 4.34 ± 3.06 | 0.067 |
No. of good‐quality blastocysts | 2.08 ± 1.79 | 1.74 ± 1.54 | 0.103 |
High‐quality blastocyst rate | 41.05% (218/531) | 40.03% (269/672) | 0.719 |
Fresh ET cycles | 61 | 101 | |
No. of embryos transferred | 1.03 ± 0.18 | 1.08 ± 0.27 | 0.192 |
Biochemical pregnancy rate, % | 68.85% (42/61) | 59.41% (60/101) | 0.228 |
Clinical pregnancy rate, % | 55.74% (34/61) | 45.54% (46/101) | 0.209 |
Frozen ET cycles | 69 | 118 | |
No. of embryos transferred | 1.61 ± 0.49 | 1.73 ± 0.45 | 0.098 |
Biochemical pregnancy rate, % | 63.77% (44/69) | 65.25% (77/118) | 0.963 |
Clinical pregnancy rate, % | 42.03% (29/69) | 41.53% (49/118) | 0.946 |
Abbreviations: ET, embryo transfer; MII, metaphase II; 2PN, two pronucleus.